Monitoring immune function after rapid corticosteroid reduction in kidney transplant recipients.
- Author:
Shi-Hai LI
1
;
Wei WANG
;
Xiao-Peng HU
;
Hang YIN
;
Liang REN
;
Xiao-Yong YANG
;
Hang LIU
;
Xiao-Dong ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adrenal Cortex Hormones; metabolism; Adult; Antibodies, Monoclonal; therapeutic use; Female; Humans; Immunosuppressive Agents; therapeutic use; Kidney Transplantation; immunology; Male; Middle Aged; Prospective Studies; Recombinant Fusion Proteins; therapeutic use; Young Adult
- From: Chinese Medical Journal 2011;124(5):679-682
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDLong-term use of steroid with large dosage might cause many adverse effects in kidney transplant patients; reducing steroid dosage to a low level for maintenance is helpful in avoiding the side-effects, but meanwhile, acute rejection may rise to be a main concern. The present research monitored the immune function changes and the incidence of acute rejection and infection after rapid steroid reduction to investigate the safety of this strategy.
METHODSA prospective trial was conducted, using tacrolimus and mycophenolate mofetil as the basic immunosuppressive regimen, in addition to antibody induction with basiliximab. Corticosteroid dosage was rapidly reduced to 10 mg/d seven days post-transplantation in the experimental group, and the standard corticosteroid therapy was employed in the control group. Patient immunity was monitored by the Immune Cell Function Assay pre- and two weeks post-transplantation. The incidence of acute rejection and infection were compared between the experimental and control group.
RESULTSComparison of intracellular adenosine triphosphate (iATP) values detected two weeks post-transplantation for the control group ((324 ± 45) ng/ml) and the experimental group ((345 ± 91) ng/ml) did not reveal a significant difference (P > 0.05). The incidence of acute rejection was analogous between groups (P > 0.05), while an increased incidence of infection was observed in the control group (53% (n = 16)) versus the experimental group (22% (n = 6), P < 0.05). Overall, recipients in the control group had longer and more recurrent infections than those in the experimental group (P < 0.05). Patients in the control group had a lower immune response ((235 ± 35) ng/ml) than those in the experimental group ((286 ± 16) ng/ml) when infection occurred (P < 0.05).
CONCLUSIONRapid reduction of steroid early after kidney transplantation does not lead to a significant rise in patient immunity. It is a safe and effective therapy for kidney transplant patients.